Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Counterfeits Hamper ED Sales In Huge China Market

This article was originally published in PharmAsia News

Executive Summary

Counterfeit copies of the three leading erectile dysfunction drugs are hindering the effort by major pharmaceutical companies to compete in that market in China. Despite a Chinese court case won by Pfizer last year upholding its patent for Viagra (sildenafil), drug makers find their sales are not keeping pace with the 30 percent increase in the Chinese market. Few men in a country with 20 percent of the world's population buy the real ED drugs because cheap copies are readily available. Eli Lilly, maker of Cialis (tadalafil) reports only 1 percent of its global sales comes from China. (Click here for more

You may also be interested in...



Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China

The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.

QUOTED. 6 August 2020. Department of Health and Social Care.

The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.

J&J’s COVID Vaccine Contract With US Bucks Trend Of Increasingly Lucrative Deals

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel